CLINICAL RESEARCH - CEREBROLYSIN

HyperMED Clinical Research  provides links with all current publications on Hyperbaric Oxygenation, LOKOMAT (Robotic Gait Assisted Walking) and other break-through we believe relevant to the objective of NeuroRecovery.

Clinical Research:  Cerebrolysin

Cerebrolysin (Cere) is a compound with neurotrophic and neuroprotective activity that causes neuronal differentiation (sprouting of axons and dendrites) and maintains the functional integrity and recovery of the nerve cell. Pre-cerebrolysin pictured above left and after cerebrolysin right.

The true mechanism, by which this drug work in such a degenerative disease is still unknown, but probably the neuronal differentiation (sprouting of axons and dendrites) and the maintenance of the functional integrity of the nerve cell play a major role in the improvement encountered in this trial. [A. Mubaidin, A. Shurbaji, A. Hadid, N. Shishani: Cerebrolysin in Steel: Richardson-Olszewski Syndrome. The Internet Journal of Neurology. 2003. Volume 2 Number 1]

HyperMED/HyperMED Cerebrolysin.pdf

• Cerebrolysin is a porcine (pig) brain derived peptide preparation; it is produced by enzymatic breakdown of purified brain proteins and consists of low molecular weight peptides and amino acids

• Cerebrolysin facilitates neurotrophic activity which has been shown to improve cognitive performance and global function in numerous neurodegenerative disorders and mental illness. Significant improvement of cognitive function, clinical global impression and increased activities of daily living were observed

• Cerebrolysin potentiates brain alpha activity, reduces slow EEG delta frequencies and improves memory performance in healthy elderly humans, suggesting that this compound activates cerebral mechanisms related to attention and memory processes.

• Cerebrolysin is a safe product administered either intravenous and or intramuscular injection. The oral Cerebrolysin product is not as effective as the IV and IM application but useful in ongoing treatment recommendations

• Cerebrolysin is a safe drug that improves the cognitive deficits and global function in patients with mild to moderate progressive neurodegenerative disease including Multiple Sclerosis, Parkinson’s Disease, Alzheimers Disease, Dementia, Acute and Chronic Stroke victims. Cerebrolysin also demonstrated significant improvement in victims of post-acute traumatic brain injury

• Cerebrolysin demonstrated significant benefit in childhood autism (89%) and cerebral palsy (mild to complex anoxic encephalopathy)

• Cerebrolysin protects against induced motor neuron damage and reduced imposed nerve death. Studies involving induced spinal cord and nerve root damage revealed significant motor recovery with Cerebrolysin

• Cerebrolysin exerts a neuro-immunotrophic activity reducing the extent of chronic nerve cell inflammation and accelerated neuronal death under pathological conditions such as those observed in acute traumatic and chronic progressive neurodegenerative diseases (progressive arthritis)

• Cerebrolysin demonstrates ‘anti-aging’ with benefits ‘improving cognition, memory function, brain metabolism with capacity

Cerebrolysin for Treatment of Neonatal Hypoxic Ischemic Encephalopathy (CerebroHIE)

Hypoxic ischemic encephalopathy HIE due to acute perinatal asphyxia remains an important cause of neurodevelopmental deficits in childhood. Infants with moderate encephalopathy have a 10 percent risk of death, and those who survive have a 30 percent risk of disabilities. Cerebrolysin is a peptide-based drug that exhibits unique neurotrophic and neuroprotective activity. Studies on the efficacy of nerve growth factor (cerebrolysin®) for treatment of different nervous system diseases were performed on adults and children.

Neuroprotective and consequent neurorehabilitative clinical outcomes, in patients treated with the pleiotropic drug cerebrolysin.

Cerebrolysin administration, as neurorehabilitative outcomes, proved to hasten, statistically significant, especially the recovery of some critical, for standing and walking, parameters. Thus encouraged, we have now initiated a comprehensive national, 5 year retrospective, multi-centre--based on unitary data acquisition frame and mathematical apparatus--study, to evaluate the results of the treatment with Cerebrolysin in traumatic brain injuries (TBI).

Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin

At week 24, Cerebrolysin improved the global clinical function significantly with all three dosages and induced significant improvements in cognition, initiation of activities of daily living (ADL) and neuropsychiatric symptoms at 10-, 30- and 60-ml doses, respectively.

Spotlight on cerebrolysin in dementia

Cerebrolysin is a parenterally administered, porcine brain-derived peptide preparation that has pharmacodynamic properties similar to those of endogenous neurotrophic factors. In several randomized, double-blind trials of up to 28 weeks' duration in patients with Alzheimer's disease, Cerebrolysin was superior to placebo in improving global outcome measures and cognitive ability.

Clinical trials